Pulmonary Dose-volume Predictors of Radiation Pneumonitis Following Stereotactic Body Radiation Therapy
Overview
Affiliations
Purpose: Radiation pneumonitis (RP) may be severe after stereotactic body radiation therapy. Our purpose was to identify pulmonary and cardiac dosimetric parameters that predicted for post-stereotactic body radiation therapy grade ≥2 RP.
Methods And Materials: A total of 335 patients with ≥3 months' follow-up were included. Normal pulmonary volume was total lungs minus gross tumor volume. Pulmonary maximum dose, mean lung dose (MLD), and the percent of lung receiving ≥x Gy for 5 to 50 Gy in 5-Gy increments were collected. Cardiac maximum dose, mean dose, volume of lung receiving ≥0.1 Gy (V0.1), V0.25 to V1, and V2.5 to V12.5 were recorded. Multivariable logistic regression with manual backward stepwise elimination was used to identify the best dosimetric predictors of toxicity. Optimal dose-volume cutoffs were isolated with recursive partitioning analysis (RPA).
Results: The grade ≥2 RP rate was 18.8%. Pulmonary V5 to V50, MLD, and cardiac V0.1 to V2.5 were significantly associated with toxicity on univariate analysis. On multivariable logistic regression, V10 was the strongest dosimetric predictor of grade ≥2 RP (odds ratio, 1.052; 95% confidence interval, 1.014-1.092; P = .007). RPA identified a 21.6% risk of grade ≥2 RP with V10 ≥6.14% (vs 3.8% with <6.14). MLD was the most significant predictor of grade ≥3 RP (odds ratio, 1.002; 95% confidence interval, 1.000-1.003; P = .031). RPA identified a 25.0% risk of grade ≥3 RP with MLD ≥7.84 Gy (vs 8.0% when <7.84 Gy).
Conclusions: With a grade ≥2 RP rate of 18.8%, lung V10 was the best predictor of grade ≥2 toxicity. MLD was the best predictor of grade ≥3 RP.
Yan Y, Zhu Y, Yang S, Qian C, Zhang Y, Yuan X Transl Lung Cancer Res. 2024; 13(5):1069-1083.
PMID: 38854946 PMC: 11157363. DOI: 10.21037/tlcr-24-328.
Intractable Pleural Effusion After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Katano A, Minamitani M, Nozawa Y, Yamashita H, Nakagawa K Cureus. 2023; 15(3):e36925.
PMID: 37128529 PMC: 10148733. DOI: 10.7759/cureus.36925.
Mangesius J, Minasch D, Fink K, Nevinny-Stickel M, Lukas P, Ganswindt U Strahlenther Onkol. 2022; 199(1):67-77.
PMID: 36515701 PMC: 9839789. DOI: 10.1007/s00066-022-02032-y.
Radiation-induced lung injury - what do we know in the era of modern radiotherapy?.
Konkol M, Sniatala P, Milecki P Rep Pract Oncol Radiother. 2022; 27(3):552-565.
PMID: 36186693 PMC: 9518776. DOI: 10.5603/RPOR.a2022.0046.
Radiation-Induced Lung Injury-Current Perspectives and Management.
Rahi M, Parekh J, Pednekar P, Parmar G, Abraham S, Nasir S Clin Pract. 2021; 11(3):410-429.
PMID: 34287252 PMC: 8293129. DOI: 10.3390/clinpract11030056.